BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and...
BioCentury | Jan 30, 2021
Distillery Therapeutics

SLC12A5, Rho kinase as targets for mutation-associated intellectual disability

DISEASE CATEGORY: Neurology INDICATION: Cognitive dysfunction Inhibiting SLC12A5, a cation-Cl− cotransporter, or Rho kinase could treat intellectual disability associated with OPHN1 mutations. In mice expressing mutant OPHN1, an SLC12A5 inhibitor tool compound prevented disease-associated disruptions in the duration...
BioCentury | Jan 26, 2021
Regulation

Jan. 25 Quick Takes: Comirnaty approved in Australia, authorized in Hong Kong; plus Albireo, Iterum and AZ

Comirnaty (BNT162b2) from BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) received provisional approval from the Australian Therapeutic Goods Administration and emergency use authorization from the Food and Health Bureau of the Hong Kong Special Administrative Region...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological cancers. While...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

A pair of deals with Merck on Monday gives Seattle Genetics $1.7 billion in cash before counting any milestones, enough to bring additional cancer programs or ADC technologies into the fold via in-licensing...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

Chinook hooks $106M, soon to test NASDAQ’s watersChinook Therapeutics Inc. raised $106 million in a venture round as it prepares to reverse-merge with Aduro Biotech Inc. (NASDAQ:ADRO). New investors in the kidney disease company include...
BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...
Items per page:
1 - 10 of 560